Cat. No.: HY-N0891

Tubeimoside II

(Synonyms: Tubeimoside-B)

Customer Review

Based on 1 Customer Validation

Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with K_d values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180.

For research use only. We do not sell to patients.

Purity: 99.90%
CAS No.: 115810-12-3
Formula: C₆₃H₉₈O₃₀
Molecular Weight:1335.43

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Tubeimoside II Chemical Structure

CAS No.: 115810-12-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[2]

RIG-I

All EGFR Isoforms :

All TGF-β Receptor Isoforms :

All RIG-I-like receptor (RLR) Isoforms :

RIG-I
MDA5

In Vitro

Tubeimoside II (1-5 μM; 24 h) dose-dependently reverses TGF-β1-induced epithelial-mesenchymal transition in retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 24 h) dose-dependently inhibits TGF-β1-induced phosphorylation of SRC and Vav2 in retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 48 h) dose-dependently inhibits TGF-β1-induced extracellular matrix adhesion of retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 48 h) inhibits TGF-β1-induced migration of retinoblastoma Y-79 and WERI-Rb-1 cells in a dose-dependent manner^[1].
Tubeimoside II (1-5 μM; 48 h) dose-dependently inhibits TGF-β1-induced invasion of retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 6 h) dose-dependently reduces TGF-β1-induced ROS production in retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 6 h) dose-dependently reduces TGF-β1-induced intracellular H₂O₂ production in retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 12 h) dose-dependently reduces TGF-β1-induced active Rac1-GTP expression in retinoblastoma Y-79 and WERI-Rb-1 cells^[1].
Tubeimoside II (1-5 μM; 12 h) inhibits TGF-β1-induced phosphorylation, oxidation and nuclear translocation of EGFR in retinoblastoma Y-79 and WERI-Rb-1 cells, while co-treatment with H₂O₂ or the EGFR activator NSC228155 reverses this effect^[1].
Tubeimoside II (0.25-1 μmol/L) exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43 and IAV-H1N1/FM1 in Caco-2-N, RAW264.7, A549 and Calu-3 cells, reduces viral load and alleviates cytopathic effects in a dose-dependent manner^[2].
Tubeimoside II exhibits broad-spectrum antiviral activity in A549 cells infected with IAV-H1N1/FM1, and this activity depends on the functional RIG-I signaling pathway, as knockout of RIG-I, MAVS or IFN-β abolishes its ability to reduce viral load and upregulate IFN-β expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

human retinoblastoma Y-79, WERI-Rb-1 cells (TGF-β1-pretreated)
Concentration:

1-5 μM
Incubation Time:

24 h
Result:

Induced the expression of the epithelial marker E-cadherin in a dose-dependent manner.
Reduced the expression of the mesenchymal marker Vimentin in a dose-dependent manner.\nReversed TGF-β1-induced phosphorylation of SRC in a dose-dependent manner.
Reversed TGF-β1-induced phosphorylation of Vav2 in a dose-dependent manner.
Maintained consistent total SRC and Vav2 expression across treatments.

Cell Migration Assay^[1]

Cell Line:

human retinoblastoma Y-79, WERI-Rb-1 cells (TGF-β1-pretreated)
Concentration:

1-5 μM
Incubation Time:

48 h
Result:

Dose-dependently inhibited the migratory ability of cells as measured by reduced wound closure over 48 h.

Cell Invasion Assay^[1]

Cell Line:

human retinoblastoma Y-79, WERI-Rb-1 cells (TGF-β1-pretreated)
Concentration:

1-5 μM
Incubation Time:

48 h
Result:

Dose-dependently inhibited the invasive ability of cells as measured by reduced numbers of cells invading through the polycarbonate filter membrane.

Western Blot Analysis^[1]

Cell Line:

human retinoblastoma Y-79, WERI-Rb-1 cells (TGF-β1-pretreated)
Concentration:

1-5 μM
Incubation Time:

12 h
Result:

Reversed TGF-β1-induced increases in active Rac1-GTP expression in a dose-dependent manner.
Maintained consistent total Rac1 expression across treatments.

Western Blot Analysis^[1]

Cell Line:

human retinoblastoma Y-79, WERI-Rb-1 cells (TGF-β1-pretreated)
Concentration:

1-5 μM
Incubation Time:

12 h (localization assay); 24 h (Western blot)
Result:

Reversed TGF-β1-induced phosphorylation of EGFR.
Reversed TGF-β1-induced oxidation of EGFR.
Reversed TGF-β1-induced nuclear translocation of EGFR.
Had inhibitory effects attenuated by co-treatment with H₂O₂ or the EGFR activator NSC228155.

In Vivo

Tubeimoside II (0.65-2.6 mg/kg; i.g.; daily; 5 days) dose-dependently reduces pulmonary viral load, restores CD4⁺/CD8⁺ T-lymphocyte levels, alleviates pulmonary inflammation, and upregulates key RIG-I signaling pathway proteins to enhance innate antiviral immunity in ICR mice infected with IAV-H1N1/FM1^[2].
Tubeimoside II (0.65-2.6 mg/kg; i.g.; daily; 5 days) dose-dependently reduces pulmonary and brain viral load, restores CD4⁺/CD8⁺ T-lymphocyte levels, alleviates pulmonary and cerebral inflammation, and upregulates key RIG-I signaling pathway proteins to enhance innate antiviral immunity in BALB/c mice infected with HCoV-OC43^[2].
Tubeimoside II (0.0075-0.11 μmol per ear; topical; single dose) inhibits TPA-induced ear edema in male ICR mice in vivo in a dose-dependent manner, achieving 100% inhibition at the highest tested dose of 0.11 μmol per ear^[3].
Tubeimoside II (12 mg/kg; i.m.; single dose, daily for 2 days, daily for 3 days) inhibits the growth of transplantable mouse S₁₈₀ tumors in BALB/c mice in a dose-dependent manner, achieving 60.1% inhibition at 12 mg/kg administered intramuscularly for 3 days^[3].
Topical Tubeimoside II (0.5 mg per painting; topical; twice weekly; 17 weeks) completely inhibits DMBA-initiated, TPA-promoted skin tumor formation in female ICR mice, while oral Tubeimoside II (0.1 g/L; p.o.; ad libitum; 17 weeks) reduces tumor number but not tumor incidence^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR (13-15 g, equal males and females, intranasal inoculation with 15 TCID₅₀ IAV-H1N1/FM1)^[2]
Dosage:

0.65-2.6 mg/kg
Administration:

i.g.; daily; 5 days
Result:

Mitigated pulmonary volume expansion and focal ground-glass opacities, with dose-dependent improvement in lung grayscale values.
Dose-dependently reduced pulmonary viral load, with significant decreases at all tested doses compared to the infected model group.
Restored CD4⁺ and CD8⁺ T-lymphocyte levels in whole blood, with the high dose (2.6 mg/kg) showing the strongest effect.
Alleviated alveolar wall thickening, interstitial congestion, edema, and inflammatory cell infiltration in lung tissue, reducing the lung index and HE pathology score in a dose-dependent manner.
Significantly decreased lung tissue levels of pro-inflammatory cytokines TNF-α, IL-1ß, IL-6, and IFN-γ in a dose-dependent manner.
Dose-dependently increased protein expression levels of PACT, RIG-I, MAVS, and IFN-ß in lung tissue.

Animal Model:

BALB/c (13-15 g, equal males and females, intranasal inoculation with 15 TCID₅₀ HCoV-OC43)^[2]
Dosage:

0.65-2.6 mg/kg
Administration:

i.g.; daily; 5 days
Result:

Mitigated pulmonary volume expansion and focal ground-glass opacities, with dose-dependent improvement in lung grayscale values.
Dose-dependently reduced pulmonary viral load, with significant decreases at all tested doses compared to the infected model group; also significantly reduced viral load in brain tissue.
Restored CD4⁺ and CD8⁺ T-lymphocyte levels in whole blood, with the high dose (2.6 mg/kg) showing the strongest effect.
Alleviated alveolar wall thickening, interstitial congestion, edema, and inflammatory cell infiltration in lung tissue, reducing the lung index and HE pathology score in a dose-dependent manner; also attenuated neuropathological alterations in brain tissue, including loosened interstitial architecture and shrunken neurons.
Significantly decreased lung tissue levels of pro-inflammatory cytokines TNF-α, IL-1ß, IL-6, and IFN-γ in a dose-dependent manner.
Dose-dependently increased protein expression levels of PACT, RIG-I, MAVS, and IFN-ß in lung tissue.

Animal Model:

ICR (male, ~8 weeks old)^[3]
Dosage:

0.0075 μmol per ear; 0.037 μmol per ear; 0.075 μmol per ear; 0.11 μmol per ear
Administration:

topical; single dose
Result:

Reduced TPA-induced ear thickness increase to 6.8 × 10^-2 mm, resulting in 37.7% inhibition.
Reduced TPA-induced ear thickness increase to 4.6 × 10^-2 mm, resulting in 56.6% inhibition.
Reduced TPA-induced ear thickness increase to 1.6 × 10^-2 mm, resulting in 84.9% inhibition.
Reduced TPA-induced ear thickness increase to 0.00 × 10^-2 mm, resulting in 100.0% inhibition.

Animal Model:

BALB/c (male and female, ~8 weeks old)^[3]
Dosage:

12 mg/kg
Administration:

i.m.; single dose; i.m.; daily; 2 days; i.m.; daily; 3 days
Result:

Reduced average tumor weight to 1.5 g, resulting in 43.3% inhibition.
Reduced average tumor weight to 1.35 g, resulting in 49.8% inhibition.
Reduced average tumor weight to 1.07 g, resulting in 60.1% inhibition.
Caused no animal mortality during the experimental course.

Chemical Information

CAS No. 115810-12-3
Appearance Solid
Molecular Weight 1335.43
Formula C₆₃H₉₈O₃₀
Color White to off-white
SMILES

OC[C@H]1O[C@](O[C@H]2[C@@H](O)C[C@@]3(C)[C@](CC[C@]4(C)[C@]3([H])CC=C5[C@@]4(C)C[C@@H](O)[C@]67[C@@]5([H])CC(C)(C)CC6)([H])[C@@]2(CO)C)([H])[C@@](O[C@@]8([H])[C@H](O)[C@@H](O)[C@](OC(C[C@](O)(C)CC(O[C@]9([H])[C@@H](O[C@@]%10([H])[C@H](O)[C@@H](O)[C@H](O)CO%10)[C@@H](O)[C@@](O[C@]%11([H])[C@@H](O)[C@@H](O)CO[C@@]%11([H])OC7=O)([H])O[C@H]9C)=O)=O)([H])CO8)([H])[C@@H](O)[C@@H]1O
Synonyms

Tubeimoside-B
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (74.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7488 mL

3.7441 mL

7.4882 mL

5 mM

0.1498 mL

0.7488 mL

1.4976 mL

10 mM

0.0749 mL

0.3744 mL

0.7488 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (1.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (299 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen Y, et al. Tubeimoside II inhibits TGF-β1-induced metastatic progression of human retinoblastoma cells through suppressing redoxosome-dependent EGFR activation. Chem Biol Interact. 2021;335:109367. [Content Brief]

[2]. Liu X, et al. A new approach to discovering a broad-spectrum anti-respiratory virus drug: Tubeimoside II modulates host factor PACT to potentiate the RIG-I antiviral pathway. Acta Pharm Sin B. 2026;16(5):3109-3127. [Content Brief]

[3]. Yu TX, et al. Structure-activity relationship of tubeimosides in anti-inflammatory, antitumor, and antitumor-promoting effects. Acta Pharmacol Sin. 2001;22(5):463-468. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.7488 mL	3.7441 mL	7.4882 mL	18.7206 mL
	5 mM	0.1498 mL	0.7488 mL	1.4976 mL	3.7441 mL
	10 mM	0.0749 mL	0.3744 mL	0.7488 mL	1.8721 mL
	15 mM	0.0499 mL	0.2496 mL	0.4992 mL	1.2480 mL
	20 mM	0.0374 mL	0.1872 mL	0.3744 mL	0.9360 mL
	25 mM	0.0300 mL	0.1498 mL	0.2995 mL	0.7488 mL
	30 mM	0.0250 mL	0.1248 mL	0.2496 mL	0.6240 mL
	40 mM	0.0187 mL	0.0936 mL	0.1872 mL	0.4680 mL
	50 mM	0.0150 mL	0.0749 mL	0.1498 mL	0.3744 mL
	60 mM	0.0125 mL	0.0624 mL	0.1248 mL	0.3120 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Tubeimoside II

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

All EGFR Isoforms

All TGF-β Receptor Isoforms

All RIG-I-like receptor (RLR) Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tubeimoside II Related Classifications

HY-N0891 Related Classifications